Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro)
Abstract
Tirzepatide (Mounjaro), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has gained widespread adoption for the management of type 2 diabetes mellitus and obesity owing to its robust efficacy in glycemic control and weight reduction. While gastrointestinal adverse effects, including nausea, vomiting, constipation, and delayed gastric emptying, are well recognized, acute small bowel obstruction represents a rare and poorly characterized complication. We report a case of a 50-year-old woman with insulin-dependent type 2 diabetes mellitus, diabetic neuropathy, and obesity who developed acute small bowel obstruction following three months of tirzepatide therapy titrated to 12.5 mg weekly. She presented with severe abdominal pain, vomiting, abdominal distension, and syncope. Imaging confirmed small bowel obstruction without evidence of perforation, ischemia, mass lesion, or an identifiable mechanical transition point. No alternative reversible etiology for bowel obstruction was identified. Conservative management with nasogastric decompression, bowel rest, and intravenous fluid resuscitation resulted in rapid clinical improvement. Tirzepatide was discontinued, and no recurrence was observed over two months of follow-up. This case underscores small bowel obstruction as a rare but potentially serious adverse effect of tirzepatide, likely mediated by impaired gastrointestinal motility inherent to incretin-based therapy.…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.